KCNH1 and breast carcinoma: Taking these observations into consideration in addition to those showing Eag1, an oncogenic factor, as a target for calcitriol [4], [5], we aimed at investigating if astemizol, a blocker of Eag1 activity, increased the potency of calcitriol antiproliferative effects in breast cancer cells.